1. Home
  2. BNBX vs NXTS Comparison

BNBX vs NXTS Comparison

Compare BNBX & NXTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BNBX

Applied DNA Sciences Inc.

N/A

Current Price

$0.47

Market Cap

3.6M

ML Signal

N/A

NXTS

Nexentis Technologies Inc. Common Stock

N/A

Current Price

$4.76

Market Cap

3.4M

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
BNBX
NXTS
Founded
1983
2009
Country
United States
Israel
Employees
26
9
Industry
Other Consumer Services
Agricultural Chemicals
Sector
Consumer Discretionary
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
3.6M
3.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BNBX
NXTS
Price
$0.47
$4.76
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
303.8K
19.6K
Earning Date
05-14-2026
05-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$253.12
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.45
$0.55
52 Week High
$6.17
$6.21

Technical Indicators

Market Signals
Indicator
BNBX
NXTS
Relative Strength Index (RSI) 34.28 53.12
Support Level $0.45 $3.92
Resistance Level $0.85 $5.31
Average True Range (ATR) 0.03 0.62
MACD 0.00 -0.17
Stochastic Oscillator 17.37 20.98

Price Performance

Historical Comparison
BNBX
NXTS

About BNBX Applied DNA Sciences Inc.

BNB Plus Corp focuses on digital asset treasury management of BNB. The group is unlocking institutional-grade access to the Binance ecosystem, delivering non-directional yield strategies and long BNB exposure, powering the future of blockchain through a transparent, actively managed BNB treasury. The Company's differentiated blends sophisticated DeFi yield generation with Binance-native opportunities, unlocking access to high-performance digital assets for investors traditionally excluded from the space.

About NXTS Nexentis Technologies Inc. Common Stock

Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.

Share on Social Networks: